Epidemiology of Neurological Complications to Nitrous Oxide Poisoning

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

135 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-10

Study Completion Date

2022-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

N2O inactivates vitamin B12, impairing its ability to act as a cofactor of methionine synthase. In addition, the elimination of vitamin B12 is increased. Neurological damage is similar to that described in combined sclerosis of the marrow, and are probably related to induce vitamin B12 deficiency. The use of N2O can then precipitate the rapid appearance of signs (neurological, psychiatric and hematological) related to a true and/ or functional vitamin B12 deficiency.

In 1978, RB Layzer described the first 3 cases of peripheral neuropathy secondary to nitrous oxide (N2O) consumption. In 2016, a team collected the 91 published cases: among these, 72 had neurological complications, and 52 had a concentration of vitamin B12 considered "low" or "normal-low"

Since then, consumption patterns seem changed due to: an increasing ease of access, the change of container (packaging in cartridge 8 grams versus bottle of 600 grams) and a usually occasional and festive consumption that seems to become solitary and regular, This change in consumption patterns is explained by an increased incidence of neurological complications, although no epidemiological work is yet available.

The objective of this work is to describe the epidemiology of this condition, to correlate it with major recent social phenomena (confinement related to the SARS-Cov2 pandemic), and finally to compare the incidence of myelopathies secondary to N2O with the incidence of other frequent inflammatory neurological diseases (autoimmune myelitis and Guillain-Barré syndrome).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biological Diagnosis and Monitoring of Chronic Nitrous Oxide Abuse

NCT05540561

Nitrous Oxide Abuse

RECRUITING

Dexanabinol in Severe Traumatic Brain Injury

NCT00129857

Traumatic Brain Injury

COMPLETED PHASE3

Systemic Nitrosative/Oxidative Stress in Patients with Acute Brain Injury

NCT04951453

Subarachnoid Hemorrhage, Aneurysmal Intracerebral Hemorrhage Traumatic Brain Injury

ACTIVE_NOT_RECRUITING

Inhaled Nitric Oxide Treatment for Aneurysmal SAH Patients With Intractable Cerebral Vasospasm

NCT04988932

SAH Inhaled Nitric Oxide Cerebral Ischemia +1 more

COMPLETED NA

Endothelial Dysfunction in Reversible Cerebral Vasoconstriction Syndrome

NCT04463212

Reversible Cerebral Vasoconstriction Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurology Department

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (≥16 years)
* Hospitalized or having consulted with the departments of Neurology or Internal Medicine for neurological phenomena related to the consumption of N2O. The neurological phenomena included are usually: neuropathies or myelopathies, However, the existence of other neurological or psychiatric signs is not a factor of exclusion: for example, headaches or cognitive or psychiatric disorders with acute onset.
* Exposure to N2O for recreational or medical reasons (Meopa anesthesia).
* Lack of alternative diagnosis other than N2O poisoning
* Consultation for neurological disorders between 01/01/2018 and 31/12/2021

Exclusion Criteria

* Minor subjects or subjects subject to a legal protection measure (guardianship, curators) during the consultation.
* Refusal to include in a study explained in the file
* Absence of N2O consumption during the 6 months preceding the appearance of signs

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No